This compound is a stereochemically defined pharmaceutical intermediate featuring a fused pyrrolo[1,2-a]pyrimidine ring system with an ester substituent. It is primarily used as a building block in the synthesis of active pharmaceutical ingredients.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1190392-23-4
(2R,5S)-tert-butyl 2-((R)-hydroxy(phenyl)methyl)-5-(4-((S)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamido)benzyl)pyrrolidine-1-carboxylate
pharmaceutical intermediate
1-(3,5-Dichloro-4-fluorophenyl)-2,2,2-trifluoroethanone
pharmaceutical intermediate
(3aR,4R,6R,6aR)-4-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-6-(hydroxymethyl)-2,2-dimethyl-6,6a-dihydro-3aH-furo[3,4-d][1,3]dioxole-4-carbonitrile
pharmaceutical intermediate
2-(3-((4-((Ethoxyimino)methyl)-5-(4-(trifluoromethoxy)phenyl)isoxazol-3-yl)methoxy)phenyl)acetic acid
pharmaceutical intermediate
4-Oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxylic acid, (S)-
research compound
Sodium (S)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxylate
pharmaceutical intermediate
methyl (6S)-4-oxo-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidine-6-carboxylate
FQHDVSMSHVCUIP-LURJTMIESA-N
COC(=O)[C@@H]1CCC2=NC=CC(=O)N12
—